Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCORED phase 3 trial of sotagliflozin in adults with type 2 diabetes, cardiovascular risk, and moderate chronic kidney disease
MOH_2017-12-18_000849Phase 3Completed
- Sponsor
- Sanofi
- Start
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) comparing Sotagliflozin with Placebo (2 arms). Primary endpoints: Major adverse cardiovascular events and Cardiovascular death or hospitalization for heart failure. Started Nov 2017; status: completed.
02
Drugs
sotagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)chronic kidney disease (CKD)
Beyond the preview
Go deeper on MOH_2017-12-18_000849.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-12-18_000849.